Merck’s quarterly revenue narrowly missed Wall Street expectations, hurt by lower-than-expected sales of its key immuno-oncology drug, Keytruda, and its diabetes medicines. The company also forecast 2017 adjusted earnings in the range of $3.72 to $3.87 per share on revenue of $38.6 billion-$40.1 billion.